Victoza for weight loss: what one year of liraglutide actually does

What did @_nrthrnlghts actually say?

Here's the twist: the video's audio is a pop song about watching kids grow up. There are no spoken health claims in the transcript at all. Every claim this fact-check needs to evaluate comes entirely from the caption, not from anything the creator said on camera.

In the caption, the creator writes that Victoza (liraglutide) "saved my life," that they have struggled with disordered eating, and that the medication helped "retrain my brain" around food-related behaviors. They describe a specific behavioral shift: choosing exercise over boredom-driven snacking. They frame this as a nearly year-long personal experience, not as medical advice. That context matters. But the claims still deserve scrutiny, because 22,000 people saw them.

Does the science back this up?

The neurological framing is actually more grounded than it sounds. GLP-1 receptor agonists like liraglutide do appear to act on reward and impulse-control circuits in the brain, not just the gut. The "retrain my brain" language is informal, but it points at something real.

A 2022 review by Blundell et al. in Obesity Reviews found that liraglutide reduces food cue reactivity and appetite-related neural signaling in the hypothalamus and limbic system. A separate 2021 study by ten Kulve et al. in Diabetes Care used fMRI to show liraglutide reduced activation in reward-related brain regions in response to food images in people with type 2 diabetes. Neither study focused specifically on disordered eating populations, which is an important gap. But the mechanism the creator is describing, reduced behavioral drive toward food, is consistent with what researchers are actually finding in neuroimaging data.

The weight loss claim is well-supported. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed liraglutide 3.0 mg produced approximately 8 percent average body weight loss over 56 weeks versus placebo. Sustained results at one year are clinically plausible.

What did they get wrong (or right)?

The creator got more right than wrong, but there are real gaps worth naming plainly.

What they got right: the behavioral observation that GLP-1 medications appear to reduce impulsive or reward-driven eating is consistent with emerging evidence. Describing this as a brain-level effect is not pseudoscience. Noting that the results persisted for nearly a year is also realistic given what the clinical trials show.

What they glossed over: Victoza is liraglutide approved at 1.8 mg for type 2 diabetes. The weight-loss approved version is Saxenda, the same molecule at 3.0 mg. The creator doesn't clarify which they're using or why, and that distinction matters for anyone watching who might seek the same treatment. GLP-1 medications in people with active disordered eating, particularly restrictive disorders, have not been rigorously studied for safety. The caption frames the medication as straightforwardly helpful for disordered eating, but clinicians remain cautious here. Using a weight-loss injection while managing disordered eating should involve a multidisciplinary care team, not just a prescriber.

The "saved my life" framing is emotionally resonant but medically unverifiable, and it sets an expectation that may not match other people's experiences.

What should you actually know?

GLP-1 receptor agonists are legitimate, well-studied medications. Liraglutide has been on the market since 2010 and has a substantial evidence base. The behavioral effects the creator describes, reduced boredom eating and increased physical activity, are plausible and have been observed in clinical settings.

But a few things need to be said clearly. First, the relationship between GLP-1 medications and disordered eating is under-researched. A 2023 commentary by Himmerich and Treasure in The Lancet Psychiatry flagged that GLP-1 drugs could potentially worsen restrictive eating patterns in vulnerable individuals, even while reducing binge or reward-driven eating in others. The population the creator belongs to may respond very differently from a general weight-loss population. Second, liraglutide carries a boxed warning for thyroid C-cell tumors in rodents, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma. Third, individual results vary considerably. The SCALE trial showed meaningful average weight loss, but a meaningful subset of participants did not respond. One person's transformation is not a predictor of yours.

If you're considering a GLP-1 medication and you have a history of disordered eating, that history belongs in your intake conversation, not after the fact.